Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Bendamustine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.96 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.96 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.96 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.96 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.96 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.96 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.96 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.96 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bendamustine SCHEMBL26319 | 0.98 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL29394147 | 0.98 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL9950832 | 0.98 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL15523734 | 0.97 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL12497247 | 0.97 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL18843 | 0.97 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL29352819 | 0.97 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL118499 | 0.96 | HDAC6 (0.96) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL16772708 | 0.95 | HDAC6 (0.94) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL23909358 | 0.94 | HDAC6 (0.92) | HDAC6HDAC1HDAC3HDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109777-A1 | METHODS OF TREATING CANCER USING SUBCUTANEOUS DOSING OF MOSUNETUZUMAB AS A MONOTHERAPY OR IN COMBINATION WITH LENALIDOMIDE | GENENTECH INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4684836-A2 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | Oryzon Genomics, S.A. (ES) | 2026-01-28 | — | — | EP | disclosed |
| EP-3429571-B1 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | ORYZON GENOMICS SA (ES) | 2025-10-08 | — | — | EP | disclosed |
| US-20250302781-A1 | METHOD FOR PRETREATING RELAPSING CANCER | VALCURIA AB (SE) | 2025-10-02 | — | — | US | disclosed |
| US-20250144024-A1 | BENDAMUSTINE SOLID DISPERSIONS AND CONTINUOUS INFUSION | VOUDOURIS VASILIOS (US) | 2025-05-08 | — | — | US | disclosed |
| EP-4529457-A1 | METHOD FOR PRETREATING RELAPSING CANCER | Valcuria AB (SE) | 2025-04-02 | — | — | EP | disclosed |
| US-20250064829-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | GENENTECH, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-20240390331-A1 | ORAL BENDAMUSTINE FORMULATIONS | TUBE PHARMACEUTICALS GMBH (AT) | 2024-11-28 | — | — | US | disclosed |
| US-20240299363-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | VOUDOURIS VASILIOS (US) | 2024-09-12 | — | — | US | disclosed |
| CN-118557751-A | Methods of treating diffuse large B-cell lymphomas using anti-CD 79B immunoconjugates | 基因泰克公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20150258069-A1 | Bendamustine Solid Dispersions And Continuous Infusion | VOUDOURIS VASILIOS (US) | 2015-09-17 | — | — | US | disclosed |
| US-9061011-B1 | Bendamustine pharmaceutical compositions | VOUDOURIS VASILIOS (US) | 2015-06-23 | — | — | US | disclosed |
| US-8987469-B2 | Process for the preparation of bendamustine | HEYL CHEMISCH-PHARMAZEUTISCHE FABRIK GMBH & CO. KG (DE) | 2015-03-24 | — | — | US | disclosed |
| WO-2015031198-A2 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | VOUDOURIS VASILIOS (US) | 2015-03-05 | — | — | WO | disclosed |
| US-20150065549-A1 | Bendamustine Pharmaceutical Compositions | VOUDOURIS VASILIOS (US) | 2015-03-05 | — | — | US | disclosed |
| EP-2690096-B1 | Process for preparation of Bendamustine | HEYL CHEM PHARM (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-20140302012-A1 | Combination Therapies for Treating Hematologic Malignancies Using Pyridopyrimidinone Inhibitors of PI3K/mTOR with Bendamustine and/or Rituximab | SANOFI (FR) | 2014-10-09 | — | — | US | disclosed |
| CN-103874494-A | combination therapy using pyridopyrimidinone inhibitors of PI3K/MTOR with bendamustine and/or rituximab to treat hematological malignancies | EXELIXIS INC | 2014-06-18 | — | — | CN | disclosed |
| US-20140031560-A1 | PROCESS FOR THE PREPARATION OF BENDAMUSTINE | HEYL CHEMISCH-PHARMAZEUTISCHE FABRIK GMBH & CO. KG (DE) | 2014-01-30 | — | — | US | disclosed |
| EP-2690096-A1 | Process for preparation of Bendamustine | HEYL Chemisch-Pharmazeutische Fabrik GmbH und Co. KG (DE) | 2014-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109777-A1 | METHODS OF TREATING CANCER USING SUBCUTANEOUS DOSING OF MOSUNETUZUMAB AS A MONOTHERAPY OR IN COMBINATION WITH LENALIDOMIDE | BCL6, BCL6B, MALT1 | HDAC6 1418/4885HDAC1 2309/4885HDAC3 1024/4885 |
| US-20250144024-A1 | BENDAMUSTINE SOLID DISPERSIONS AND CONTINUOUS INFUSION | WEE1, SLC29A2, SLC29A1 | HDAC6 1618/4885HDAC1 2772/4885HDAC3 4295/4885 |
| US-20150065549-A1 | Bendamustine Pharmaceutical Compositions | FLT3, BLK, FOLR2 | HDAC6 1308/4885HDAC1 3917/4885HDAC3 4356/4885 |
| US-20250064829-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | CD79B, CD99, BCL9 | HDAC6 662/4885HDAC1 1930/4885HDAC3 2371/4885 |
| US-20140302012-A1 | Combination Therapies for Treating Hematologic Malignancies Using Pyridopyrimidinone Inhibitors of PI3K/mTOR with Bendamustine and/or Rituximab | BTK, MTOR, BCL6 | HDAC6 723/4885HDAC1 764/4885HDAC3 1362/4885 |
| US-20150258069-A1 | Bendamustine Solid Dispersions And Continuous Infusion | WEE1, SLC29A2, SLC29A1 | HDAC6 1618/4885HDAC1 2772/4885HDAC3 4295/4885 |
| US-20140031560-A1 | PROCESS FOR THE PREPARATION OF BENDAMUSTINE | OGDH, GCDH, BPGM | HDAC6 993/4885HDAC1 1465/4885HDAC3 1407/4885 |
| US-20240390331-A1 | ORAL BENDAMUSTINE FORMULATIONS | BHMT, MTHFD1, ABCB1 | HDAC6 795/4885HDAC1 2182/4885HDAC3 2480/4885 |
| US-20240299363-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | FLT3, BLK, FOLR2 | HDAC6 1308/4885HDAC1 3917/4885HDAC3 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.